OncoTriage. Поиск наилучшего лечения для вашего пациента

Миелодисплазии

Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients.

Luspatercept has been approved for the treatment of anaemia in transfusion-dependent (TD) patients with lower risk (LR) myelodysplastic syndromes (MDS) after erythroid-stimulated agent (ESA) failure, according to the results of the MEDALIST trial...

DOI: 10.1111/bjh.20102

Bouchla A, Papageorgiou SG, Kotsianidis I, Diamantopoulos P, Gavriilaki E, Bouronikou E, Symeonidis A, Zikos P, Cetiner M, Vlachaki E, Kostourou A, Galanopoulos A, Hatzimichael E, Vervesou EC, Bozdağ SC, Viniou NA, Christoulas D, Dellatola M, Papaioa

British journal of haematology, 2025-05-07

Successful treatment of multi-hit TP53-mutated myelodysplastic syndromes with erythroid predominance using allogeneic stem cell transplantation and ruxolitinib.

TP53-mutated myelodysplastic syndrome (MDS) and acute erythroid leukemia (AEL) with complex karyotype have a very poor prognosis...

DOI: 10.1007/s00277-025-06383-1

Oshima S, Kanda J, Takeda J, Sakamoto T, Mizumoto C, Yamashita K, Nannya Y, Ogawa S, Takaori-Kondo A

Annals of hematology, 2025-05-08

Наверх

Миелодисплазии

Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients.

Successful treatment of multi-hit TP53-mutated myelodysplastic syndromes with erythroid predominance using allogeneic stem cell transplantation and ruxolitinib.

Свяжитесь с нами

Вход в аккаунт

Восстановление пароля